According to a sizable study, Eli Lilly and Co.’s experimental Alzheimer’s medicine appeared to reduce the disease’s progression.
According to a news statement from Lilly, persons with early-stage Alzheimer’s who received infusions of donanemab shown a 35% slower loss in cognitive function than those who received a placebo during the 18-month experiment.
The medication is made to target and eliminate beta-amyloid, a sticky protein that accumulates form plaques in the brain and is one of the main symptoms of Alzheimer’s disease.
Leqembi, an amyloid-targeting medication from Eisai and Biogen, recently entered the market with certain safety concerns, including brain swelling or minor brain bleeding, and similar findings suggesting it might very slightly reduce Alzheimer’s.
That danger also exists with donanemab. According to Lilly, two study participants died as a result of the brain adverse effects, while a third passed away following a critical case.
There hasn’t been any external expert review of the preliminary study findings. Lilly, based in Indianapolis, wants the Food and Drug Administration to approve the medication and hopes to provide more information during an international Alzheimer’s summit this summer.
JOIN US ON WHAT'SAPP, TO GET INSTANT STATUS UPDATES AND BE IN THE KNOW.
CLICK HERE
